Diagnosing and managing oropharyngeal candidiasis

Infections in Medicine

Volumn 24, Issue 10, 2007, Pages 427-436

  Vazquez, Jose A ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Antifungal agents; Azoles; Oropharyngeal candidiasis

Indexed keywords

AMPHOTERICIN B; ANTACID AGENT; ANTIFUNGAL AGENT; ASTEMIZOLE; CIMETIDINE; CISAPRIDE; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOSPORIN A; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; PHENYTOIN; POSACONAZOLE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RANITIDINE; RIFABUTIN; RIFAMPICIN; SUCRALFATE; TERFENADINE;

ARTICLE; CANDIDA; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; ESOPHAGUS DISEASE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; INFECTION RISK; LIVER TOXICITY; OROPHARYNX CANDIDIASIS; QT PROLONGATION; RISK FACTOR; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

EID: 39749160358     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hippocrates. Epidemics, Book 3. Adams F, trans. Baltimore: Williams & Wilkins; 1939.
2. Parrot J. Clinique des nouveau-nés: L'athrepsie: Leçons recueillies par Dr Troisier. Paris: G. Masson; 1877.
3. Trousseau A. Lectures on Clinical Medicine, Delivered at the Hotel-Dieu, Paris. Cormack JR, trans; ed from 1865 ed vol 2. London: New Sydenham Society; 1869.
4. Langenbeck B. Auffingung von Pilzen aus der Schleimhaut der Speiseröhre einer Typhus-Leiche. Neue Not Geb Natur-u-Heilk (Froriep). 1839;12:145-147.
5. Berg FT. GM Torsk hos Barn. Stockholm: L. J. Hjerta; 1846.
6. Odds FC. Candida and Candidosis. A Review and Bibliography. 2nd ed. London: Baillière Tindall; 1988.
7. Feigal DW, Katz MH, Greenspan D, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS. 1991;5:519-525.
8. Vazquez JA, Sobel JD. Mucosal candidiasis. Infect Dis Clin North Am. 2002;16:793-820.
9. Kleinegger CL, Lockhart SR, Vargas K, Soll DR. Frequency, intensity, species, and strains of oral Candida vary as a function of host age. J Clin Microbiol. 1996;34:2246-2254.
10. Johnston RD, Chick EW, Johnston NS, Jarvis MA. Asymptomatic quantitative increase of Candida albicans in the oral cavity: predisposing conditions. South Med J. 1967;60:1244-1247.
11. Cohen R, Roth FJ, Delgado E, et al. Fungal flora of the human small and large intestine. N Engl J Med. 1969;280:638-641.
12. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133-163.
13. Vazquez JA, Sobel JD. Candidiasis. In: Dismukes WD, Pappas PG, Sobel JD, eds. Clinical Mycology. New York: Oxford University Press; 2003:143-187.
14. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5 year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;45:1735-1745.
15. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C albicans. Clin Microbiol Rev. 1999;12:80-96.
16. Barchiesi F, Morbiducci V, Ancarani F, Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol. 1993;9:455-456.
17. van 't Wout JW. Fluconazole treatment of candidal infections caused by non-albicans Candida species. Eur J Clin Microbiol Infect Dis. 1996;15:238-242.
18. Stevens DA. Fungal infections in AIDS patients. Br J Clin Pract. 1990;44(suppl 71):11-22.
19. Chandler FW. Pathology of the mycoses in patients with the acquired immunodeficiency syndrome (AIDS). Curr Top Med Mycol. 1985;1:1-23.
20. Melbye M, Schønheyder H, Kestens L, et al. Carriage of oral Candida albicans associated with a high number of circulating suppressor T lymphocytes. J Infect Dis. 1985;152:1356-1357.
21. 2 enhances and gamma interferon inhibits germ tube formation in Candida albicans. Infect Immun. 1990;58:260-262.
22. Tapper-Jones LM, Aldred MJ, Walker DM, Hayes TM. Candidal infections and populations of Candida albicans in mouths of diabetics. J Clin Pathol. 1981;34:706-711.
23. Fitzpatrick JJ, Topley HE. Ampicillin therapy and Candida outgrowth. Am J Med Sci. 1966;252:310-313.
24. Samaranayake LP. Nutritional factors and oral candidosis. J Oral Pathol. 1986;15:61-65.
25. 2-receptor antagonist. Digestion. 1983;28:158-163.
26. Sandford GR, Merz WG, Wingard JR, et al. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis. 1980;142:503-509.
27. Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials. 2000;1:47-59.
28. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis. 1998;26:259-274.
29. Pons V, Greenspan D, Debruin M, et al. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. J Acquir Immune Defic Syndr. 1993;6:1311-1316.
30. Vazquez JA, Sobel JD. Epidemiologic overview of resistance to oral antifungal agents in the immunocompromised host [abstract]. Excerpta Medica. 1997;1-11.
31. Hughes WT, Bartley DL, Patterson GG, Tufenkeji H. Ketoconazole and candidiasis: a controlled study. J Infect Dis. 1983;147:1060-1063.
32. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract. 2004;58:612-624.
33. Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother. 1998;42:1862-1865.
34. Graybill JR, Vazquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med. 1998;104:33-39.
35. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42:1179-1186.